DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Ecolab's (ECL) robust performance across the majority of its segments drives its first-quarter sales despite business challenges.
QIAGEN (QGEN) Q1 results are driven by solid growth in consumables and ongoing higher instruments placements.